Search Medical Condition
Please enter condition
Please choose location from dropdown

Rock Hill, South Carolina Clinical Trials

A listing of Rock Hill, South Carolina clinical trials actively recruiting patient volunteers.

RESULTS

Found (40) clinical trials

The purpose of this Study is to find out if the study drug ruxolitinib (“Study Drug” or ruxolitinib) is safe and effective compared to anagrelide hydrochloride (also known as Agrylin® or anagrelide), in people who have Essential Thrombocythemia (ET) and are resistant to or intolerant of Hydroxyurea. 

Phase

5.95 miles

Learn More »

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.

Phase

5.95 miles

Learn More »

A Study of the Effect of a Disease-Specific Migraine Smart Phone Application (App) on Participant Care

The purpose of this study is to determine whether using a smart phone application to foster communication between study participants and their doctor will impact care. Participants must have a history of migraine or have recently been prescribed a common medicine to treat migraine. The study will last about one ...

Phase N/A

8.22 miles

Learn More »

Psoriasis Longitudinal Assessment and Registry (PSOLAR)

PSOLAR is an 8 year registry study. A registry is an observational study that evaluates the status of a disease. This registry study will only include patients who volunteer to take part. About 4000 infliximab-exposed patients, 4000 ustekinumab-exposed patients and as well as a comparable number of patients (4000) on ...

Phase N/A

9.42 miles

Learn More »

Evaluation of Major Cardiovascular Events in Patients With or at High Risk for Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in patients who are statin intolerant.

Phase

9.75 miles

Learn More »

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

A multi-regional clinical trial with participating sites planned in the following countries pending approval from the applicable oversight authorities: Argentina Brazil Bulgaria Canada Colombia Czech Republic Denmark France Germany Hungary India Israel Japan Mexico Netherlands Poland Romania Russian Federation Slovakia South Africa Spain Ukraine United Kingdom United States

Phase

9.75 miles

Learn More »

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further explore the incidence of selected safety- related outcomes and to further monitor the overall safety profile of fingolimod under conditions of routine ...

Phase N/A

9.75 miles

Learn More »

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

The purpose of this study is to evaluate the efficacy of pimavanserin by comparing pimavanserin with placebo in preventing a relapse of psychotic symptoms in subjects with dementia-related psychosis and who were stabilized after 12 weeks of open label pimavanserin treatment.

Phase

9.75 miles

Learn More »

Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

This is a multicenter, 3-arm, randomized, placebo-controlled, double-blind, parallel-group study of ADS-5102 (amantadine extended release [ER] capsules) in MS patients with walking impairment. ADS-5102 will be administered once daily at bed time.

Phase

9.75 miles

Learn More »

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition

Patients with chronic kidney disease, who have evidence of systemic inflammation with increased cardiovascular risk, will be enrolled into this trial. The purpose of this trial is to determine a dose to select for a potential cardiovascular outcome trial with Ziltivekimab. Doses to be tested will be 7.5 mg, 15 ...

Phase

9.75 miles

Learn More »